On Target is a recurring feature from STAT that dives deep into the most promising drug targets in oncology.
The hunt for cancer cures has, to a large degree, been a hunt for biomarkers — DNA, peptides, RNA, proteins or more — that might set tumor cells apart from healthy tissue. With the right biomarker, scientists can find cancers earlier, monitor a treatment’s progress, or predict if a certain therapy will work for a given patient. The trouble is that for many cancers, the known biomarkers have been a disappointment, particularly for early cancer detection.
“You see all sorts of research groups looking at natural biomarkers,” said Amin Aalipour, a resident physician at Brigham and Women’s Hospital and a synthetic biology researcher. “There’s limits to what we can do when you rely on what the tumor is willing to tell us.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect